$MIST News

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026

Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3

Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound

Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary

Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript

Milestone Pharmaceuticals Q2 Earnings Call Highlights

Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals shares tumble after Q2 earnings miss

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $559.000K Miss $816.667K Estimate

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)